Advertisement

Journal of Zhejiang University-SCIENCE B

, Volume 20, Issue 10, pp 838–848 | Cite as

IGF-1R/β-catenin signaling axis is involved in type 2 diabetic osteoporosis

  • Zhi-da Zhang
  • Hui Ren
  • Wei-xi Wang
  • Geng-yang Shen
  • Jin-jing Huang
  • Mei-qi Zhan
  • Jing-jing Tang
  • Xiang Yu
  • Yu-zhuo Zhang
  • De Liang
  • Zhi-dong Yang
  • Xiao-bing JiangEmail author
Article
  • 5 Downloads

Abstract

Insulin-like growth factor-1 receptor (IGF-1R) is involved in both glucose and bone metabolism. IGF-1R signaling regulates the canonical Wnt/β-catenin signaling pathway. In this study, we investigated whether the IGF-1R/ β-catenin signaling axis plays a role in the pathogenesis of diabetic osteoporosis (DOP). Serum from patients with or without DOP was collected to measure the IGF-1R level using enzyme-linked immunosorbent assay (ELISA). Rats were given streptozotocin following a four-week high-fat diet induction (DOP group), or received vehicle after the same period of a normal diet (control group). Dual energy X-ray absorption, a biomechanics test, and hematoxylin-eosin (HE) staining were performed to evaluate bone mass, bone strength, and histomorphology, respectively, in vertebrae. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were performed to measure the total and phosphorylation levels of IGF-1R, glycogen synthase kinase-3β (GSK-3β), and β-catenin. The serum IGF-1R level was much higher in patients with DOP than in controls. DOP rats exhibited strikingly reduced bone mass and attenuated compression strength of the vertebrae compared with the control group. HE staining showed that the histo-morphology of DOP vertebrae was seriously impaired, which manifested as decreased and thinned trabeculae and increased lipid droplets within trabeculae. PCR analysis demonstrated that IGF-1R mRNA expression was significantly up-regulated, and western blotting detection showed that phosphorylation levels of IGF-1R, GSK-3β, and β-catenin were enhanced in DOP rat vertebrae. Our results suggest that the IGF-1R/β-catenin signaling axis plays a role in the pathogenesis of DOP. This may contribute to development of the underlying therapeutic target for DOP.

Key words

Diabetic osteoporosis Insulin-like growth factor-1 receptor (IGF-1R) Signaling axis Pathogenesis 

IGF-1R/β-catenin 信号通路在 2 型糖尿病性骨质疏松中的作用

概要

目 的

探讨胰岛素样生长因子-1 受体 (IGF-1R)/β-联蛋白 (β-catenin) 信号通路是否在糖尿病性骨质疏松 (DOP) 病理机制中起作用。

创新点

发现 IGF-1R/β-catenin 信号通路在 DOP 病理机制中起作用, 可能是 DOP 潜在的治疗靶点。

方 法

收集 DOP 患者血清, 使用酶联免疫吸附测定 (ELISA) 法检测 IGF-1R 水平。 DOP 大鼠在 4 周高脂饲料喂养后给予链脲佐菌素建模, 对照组大鼠在普通饲料喂养 4 周后再给予链脲佐菌素溶媒 (柠檬酸钠缓冲液)。 应用双能 X 线吸收法、 生物力学测试和苏木精-伊红 (HE) 染色法分别评估椎体骨量、 骨强度和骨组织形态。 使用实时定量聚合酶链反应 (qRT-PCR) 和蛋白印迹法 (western blotting) 测定 IGF-1R、 糖原合成酶激酶-3β (GSK-3β)和 β-catenin 表达及其蛋白磷酸化水平。

结 论

DOP 患者血清 IGF-1R 较对照组高。 DOP 大鼠骨量、 压缩强度明显减小, HE 染色显示 DOP 椎体骨组织形态明显受损, IGF-1R 信使 RNA (mRNA) 表达上调, IGF-1R、 GSK-3β 和 β-catenin 蛋白磷酸化增加。 由此可见, IGF-1R/β-catenin 信号通路在 DOP 的病理机制中起作用, 该发现将有利于后期 DOP 治疗靶点的开发。

关键词

糖尿病性骨质疏松 胰岛素样生长因子-1 受体 信号通路 发病机制 

CLC number

R587.2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgments

We thank the specific pathogen free (SPF) animal laboratory of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, for providing the experimental platform.

Contributors

Zhi-da ZHANG, Hui REN, and Xiao-bing JIANG designed this study. Wei-xi WANG, Geng-yang SHEN, Jin-jing HUANG, Mei-qi ZHAN, and Yu-zhuo ZHANG performed these experiments. Jing-jing TANG and Xiang YU searched the relative literature and reviewed the methods for model establishment, Zhi-da ZHANG and Hui REN conducted statistical analysis. Zhi-da ZHANG prepared this manuscript. De LIANG and Zhi-dong YANG reviewed and edited manuscript. All authors have read and approved this manuscript. Therefore, all authors have full access to all the data in the study and take responsibility for the integrity and security of the data.

Compliance with ethics guidelines

Zhi-da ZHANG, Hui REN, Wei-xi WANG, Geng-yang SHEN, Jin-jing HUANG, Mei-qi ZHAN, Jing-jing TANG, Xiang YU, Yu-zhuo ZHANG, De LIANG, Zhi-dong YANG, and Xiao-bing JIANG declare that they have no conflict of interest.

All institutional and national guidelines for the care and use of laboratory animals were followed. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.

References

  1. Agholme F, Aspenberg P, 2011. Wnt signaling and orthopedics, an overview. Acta Orthop, 82(2):125–130. https://doi.org/10.3109/17453674.2011.572252CrossRefGoogle Scholar
  2. American Diabetes Association, 2016. Standards of medical care in diabetes—2016 abridged for primary care providers. Clin Diabetes, 34(1):3–21. https://doi.org/10.2337/diaclin.34.1.3CrossRefGoogle Scholar
  3. Boucher J, Kleinridders A, Kahn CR, 2014. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol, 6(1):a009191. https://doi.org/10.1101/cshperspect.a009191CrossRefGoogle Scholar
  4. Boura-Halfon S, Shuster-Meiseles T, Beck A, et al., 2010. A novel domain mediates insulin-induced proteasomal degradation of insulin receptor substrate 1 (IRS-1). Mol Endocrinol, 24(11):2179–2192. https://doi.org/10.1210/me.2010-0072CrossRefGoogle Scholar
  5. Bozic J, Markotic A, Cikes-Culic V, et al., 2018. Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: implications of glycosphingolipid metabolism in pathophysiology of diabetes. J Diabetes, 10(2):130–139. https://doi.org/10.1111/1753-0407.12569CrossRefGoogle Scholar
  6. Cheng PW, Chen YY, Cheng WH, et al., 2015. Wnt signaling regulates blood pressure by downregulating a GSK-3β-mediated pathway to enhance insulin signaling in the central nervous system. Diabetes, 64(10):3413–3424. https://doi.org/10.2337/db14-1439CrossRefGoogle Scholar
  7. Cheng YY, Liu SC, Zhang X, et al., 2016. Expression profiles of IGF-1R gene and polymorphisms of its regulatory regions in different pig breeds. Protein J, 35(3):231–236. https://doi.org/10.1007/s10930-016-9666-xCrossRefGoogle Scholar
  8. Cosman F, de Beur SJ, LeBoff MS, et al., 2014. Clinician’s guide to prevention and treatment of osteoporosis. Oste-oporos Int, 25(10):2359–2381. https://doi.org/10.1007/s00198-014-2794-2CrossRefGoogle Scholar
  9. Daniele G, Winnier D, Mari A, et al., 2015. Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism. Diabetes Care, 38(8):1509–1517. https://doi.org/10.2337/dc14-2989CrossRefGoogle Scholar
  10. de Meyts P, Whittaker J, 2002. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov, 1(10):769–783. https://doi.org/10.1038/nrd917CrossRefGoogle Scholar
  11. Desbois-Mouthon C, Cadoret A, Blivetvan Eggelpoël MJ, et al., 2001. Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation. Oncogene, 20(2):252–259. https://doi.org/10.1038/sj.onc.1204064CrossRefGoogle Scholar
  12. Engberding N, San Martin A, Martin-Garrido A, et al., 2009. Insulin-like growth factor-1 receptor expression masks the antiinflammatory and glucose uptake capacity of insulin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 29(3):408–415. https://doi.org/10.1161/ATVBAHA.108.181727CrossRefGoogle Scholar
  13. Flanagan AM, Brown JL, Santiago CA, et al., 2008. High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem, 19(8): 505–513. https://doi.org/10.1016/j.jnutbio.2007.06.005CrossRefGoogle Scholar
  14. Fowlkes JL, Nyman JS, Bunn RC, et al., 2013. Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes. Bone, 57(1):36–40. https://doi.org/10.1016/j.bone.2013.07.017CrossRefGoogle Scholar
  15. Fulzele K, DiGirolamo DJ, Liu ZY, et al., 2007. Disruption of the insulin-like growth factor type 1 receptor in osteo-blasts enhances insulin signaling and action. J Biol Chem, 282(35):25649–25658. https://doi.org/10.1074/jbc.M700651200CrossRefGoogle Scholar
  16. Geng YT, Ju YF, Ren FL, et al., 2014. Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/β-catenin signaling through blocking autophagic degradation of Dishevelled2. J Biol Chem, 289(16):11230–11241. https://doi.org/10.1074/jbc.M113.544999CrossRefGoogle Scholar
  17. Gheibi S, Kashfi K, Ghasemi A, 2017. A practical guide for induction of type-2 diabetes in rat: incorporating a high-fat diet and streptozotocin. Biomed Pharmacother, 95:605–613. https://doi.org/10.1016/j.biopha.2017.08.098CrossRefGoogle Scholar
  18. Hough FS, Pierroz DD, Cooper C, et al., 2016. MECHANISMS IN ENDOCRINOLOGY: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol, 174(4):R127–R138. https://doi.org/10.1530/EJE-15-0820CrossRefGoogle Scholar
  19. Ikeda S, Kishida S, Yamamoto H, et al., 1998. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J, 17(5):1371–1384. https://doi.org/10.1093/emboj/17.5.1371CrossRefGoogle Scholar
  20. Iyer S, Ambrogini E, Bartell SM, et al., 2013. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest, 123(8):3409–3419. https://doi.org/10.1172/JCI68049CrossRefGoogle Scholar
  21. Janghorbani M, Feskanich D, Willett WC, et al., 2006. Prospective study of diabetes and risk of hip fracture: the nurses’ health study. Diabetes Care, 29(7):1573–1578. https://doi.org/10.2337/dc06-0440CrossRefGoogle Scholar
  22. Jiao YK, Wang XQ, Jiang X, et al., 2017. Antidiabetic effects of Morus alba fruit polysaccharides on high-fat diet- and streptozotocin-induced type 2 diabetes in rats. J Eth-nopharmacol, 199:119–127. https://doi.org/10.1016/j.jep.2017.02.003CrossRefGoogle Scholar
  23. Kavran JM, McCabe JM, Byrne PO, et al., 2014. How IGF-1 activates its receptor. eLife, 3:e03772. https://doi.org/10.7554/eLife.03772CrossRefGoogle Scholar
  24. Kim IG, Kim SY, Choi SI, et al., 2014. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene, 33(30):3908–3917. https://doi.org/10.1038/onc.2013.373CrossRefGoogle Scholar
  25. Krishnan V, Bryant HU, MacDougald OA, 2006. Regulation of bone mass by Wnt signaling. J Clin Invest, 116(5): 1202–1209. https://doi.org/10.1172/JCI28551CrossRefGoogle Scholar
  26. Leng SH, Zhang WS, Zheng YB, et al., 2010. Glycogen syn-thase kinase 3β mediates high glucose-induced ubiquiti-nation and proteasome degradation of insulin receptor substrate 1. J Endocrinol, 206(2):171–181. https://doi.org/10.1677/JOE-09-0456CrossRefGoogle Scholar
  27. Li BX, Wang Y, Liu Y, et al., 2013. Altered gene expression involved in insulin signaling pathway in type II diabetic osteoporosis rats model. Endocrine, 43(1):136–146. https://doi.org/10.1007/s12020-012-9757-1CrossRefGoogle Scholar
  28. Liu XJ, Xu Q, Wang XM, et al., 2015. Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model. Pharmacol Res, 93:43–51. https://doi.org/10.1016/j.phrs.2015.01.001CrossRefGoogle Scholar
  29. Looker AC, Eberhardt MS, Saydah SH, 2016. Diabetes and fracture risk in older U.S. adults. Bone, 82:9–15. https://doi.org/10.1016/j.bone.2014.12.008CrossRefGoogle Scholar
  30. Lu JM, Wang YF, Yan HL, et al., 2016. Antidiabetic effect of total saponins from Polygonatum kingianum in streptozotocin-induced daibetic rats. J Ethnopharmacol, 179:291–300. https://doi.org/10.1016/j.jep.2015.12.057CrossRefGoogle Scholar
  31. Ma R, Wang L, Zhao B, et al., 2017. Diabetes perturbs bone microarchitecture and bone strength through regulation of Sema3A/IGF-1/β-catenin in rats. Cell Physiol Biochem, 41(1):55–66. https://doi.org/10.1159/000455936CrossRefGoogle Scholar
  32. Napoli N, Chandran M, Pierroz DD, et al., 2017. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev En-docrinol, 13(4):208–219. https://doi.org/10.1038/nrendo.2016.153CrossRefGoogle Scholar
  33. NCD Risk Factor Collaboration, 2016. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet, 387(10027):1513–1530. https://doi.org/10.1016/S0140-6736(16)00618-8CrossRefGoogle Scholar
  34. Palsgaard J, Emanuelli B, Winnay JN, et al., 2012. Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). J Biol Chem, 287(15):12016–12026. https://doi.org/10.1074/jbc.M111.337048CrossRefGoogle Scholar
  35. Pelosi P, Lapi E, Cavalli L, et al., 2017. Bone status in a patient with insulin-like growth factor-1 receptor deletion syndrome: bone quality and structure evaluation using dual-energy X-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography. Front Endocrinol (Lausanne), 8:227. https://doi.org/10.3389/fendo.2017.00227CrossRefGoogle Scholar
  36. Reed MJ, Meszaros K, Entes LJ, et al., 2000. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism, 49(11):1390–1394. https://doi.org/10.1053/meta.2000.17721CrossRefGoogle Scholar
  37. Rota LM, Wood TL, 2015. Crosstalk of the insulin-like growth factor receptor with the Wnt signaling pathway in breast cancer. Front Endocrinol (Lausanne), 6:92. https://doi.org/10.3389/fendo.2015.00092CrossRefGoogle Scholar
  38. Rota LM, Albanito L, Shin ME, et al., 2014. IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res, 74(19):5668–5679. https://doi.org/10.1158/0008-5472.CAN-14-0970CrossRefGoogle Scholar
  39. Schlupf J, Steinbeisser H, 2014. IGF antagonizes the Wnt/ β-catenin pathway and promotes differentiation of extra-embryonic endoderm. Differentiation, 87(5):209–219. https://doi.org/10.1016/j.diff.2014.07.003CrossRefGoogle Scholar
  40. Schwartz AV, Hillier TA, Sellmeyer DE, et al., 2002. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care, 25(10):1749–1754. https://doi.org/10.2337/diacare.25.10.1749CrossRefGoogle Scholar
  41. Siddle K, 2012. Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Front Endocrinol (Lausanne), 3:34. https://doi.org/10.3389/fendo.2012.00034CrossRefGoogle Scholar
  42. Slaaby R, Schäffer L, Lautrup-Larsen I, et al., 2006. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem, 281(36):25869–25874. https://doi.org/10.1074/jbc.M605189200CrossRefGoogle Scholar
  43. Solomon-Zemler R, Basel-Vanagaite L, Steier D, et al., 2017. A novel heterozygous IGF-1 receptor mutation associated with hypoglycemia. Endocr Connect, 6(6):395–403. https://doi.org/10.1530/EC-17-0038CrossRefGoogle Scholar
  44. Srinivasan K, Viswanad B, Asrat L, et al., 2005. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res, 52(4):313–320. https://doi.org/10.1016/j.phrs.2005.05.004CrossRefGoogle Scholar
  45. Sroga GE, Wu PC, Vashishth D, 2015. Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone. PLoS ONE, 10(1):e0117046. https://doi.org/10.1371/journal.pone.0117046CrossRefGoogle Scholar
  46. Szkudelski T, 2012. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood), 237(5):481–490. https://doi.org/10.1258/ebm.2012.011372CrossRefGoogle Scholar
  47. Thrailkill KM, Lumpkin CK Jr, Bunn RC, et al., 2005. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab, 289(5): E735–E745. https://doi.org/10.1152/ajpendo.00159.2005CrossRefGoogle Scholar
  48. Yan Y, Du CH, Li ZY, et al., 2018. Comparing the antidiabetic effects and chemical profiles of raw and fermented Chinese Ge-Gen-Qin-Lian decoction by integrating untargeted metabolomics and targeted analysis. Chin Med, 13(1):54. https://doi.org/10.1186/s13020-018-0208-7CrossRefGoogle Scholar
  49. Zhang ZD, Ren H, Shen GY, et al., 2016. Animal models for glucocorticoid-induced postmenopausal osteoporosis: an updated review. Biomed Pharmacother, 84:438–446. https://doi.org/10.1016/j.biopha.2016.09.045CrossRefGoogle Scholar
  50. Zhao HH, Li ZG, Tian GH, et al., 2013. Effects of traditional Chinese medicine on rats with Type II diabetes induced by high-fat diet and streptozotocin: a urine metabonomic study. Afr Health Sci, 13(3):673–681. https://doi.org/10.4314/ahs.v13i3.22Google Scholar

Copyright information

© Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Zhi-da Zhang
    • 1
  • Hui Ren
    • 2
  • Wei-xi Wang
    • 1
  • Geng-yang Shen
    • 2
  • Jin-jing Huang
    • 1
  • Mei-qi Zhan
    • 1
  • Jing-jing Tang
    • 2
  • Xiang Yu
    • 1
  • Yu-zhuo Zhang
    • 3
  • De Liang
    • 2
  • Zhi-dong Yang
    • 2
  • Xiao-bing Jiang
    • 2
    • 4
    Email author
  1. 1.The First Clinical SchoolGuangzhou University of Chinese MedicineGuangzhouChina
  2. 2.Department of Spinal Surgerythe First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhouChina
  3. 3.School of Basic MedicineGuangzhou University of Chinese MedicineGuangzhouChina
  4. 4.Lingnan Medical Research Center of Guangzhou University of Chinese MedicineGuangzhouChina

Personalised recommendations